Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Aug 03, 2026
Why Is Sportradar Group AG (SRAD) Stock Down -19.53% Today?

Why Is Sportradar Group AG (SRAD) Stock Down -19.53% Today?

Key Takeaways

  • SRAD shares plunged approximately 19.5% after the sports data provider reported disappointing second-quarter 2026 results and lowered its full-year revenue growth outlook.
  • The company swung to a net loss of roughly €4 million, driven primarily by unrealized foreign currency losses tied to U.S. dollar-denominated sports rights.
  • Revenue of €378 million rose 19% year-over-year but came in below the consensus analyst forecast, rattling investor confidence.
  • Full-year constant-currency revenue growth guidance was trimmed to 19%–21%, down from the prior range of 23%–25%.
  • A broader backdrop of analyst downgrades and an ongoing securities class-action lawsuit have compounded selling pressure on the stock, which was already down roughly 39% year-to-date before this earnings-driven selloff.
  • Traders are now watching for management's commentary on the earnings call, any further analyst revisions, and developments in the company's partnership pipeline.

Opening Summary

SRAD — Sportradar Group AG, a global sports technology company that supplies real-time data, analytics, and betting solutions to the sports wagering and media industries — cratered roughly 19.5% in Monday's trading session. As of midday, shares were changing hands near $11.70, down sharply from Friday's close of $14.54. The selloff was triggered by the company's second-quarter 2026 earnings release, which revealed a swing to a quarterly loss, a top-line miss versus Wall Street expectations, and a downward revision to full-year revenue growth guidance.

Q2 Earnings Miss: Loss, Revenue Shortfall, and FX Headwinds

Sportradar reported a comprehensive loss of approximately €4 million for the second quarter, a stark reversal from the €49 million profit booked in the same period a year earlier. The loss was driven in large part by unrealized foreign currency losses — specifically a €9 million FX headwind tied to U.S. dollar-denominated sports rights, versus a €54 million FX gain in the prior-year quarter. Severance costs linked to cost-efficiency initiatives also weighed on the bottom line.

While total revenue increased 19% year-over-year to €378 million, the figure fell short of the roughly €382 million consensus estimate. The company's Betting Technology & Solutions segment grew 21%, fueled by contributions from the IMG ARENA acquisition and new customer uptake. However, moderating growth in the U.S. market and unfavorable currency movements partially offset those gains. Sports Content, Technology & Services revenue rose just 9%, with the sports-performance sub-segment declining 13%.

On an adjusted basis, the company posted a loss of €0.01 per share, missing the consensus forecast for a €0.06 profit — an earnings surprise of approximately -117%.

Lowered Full-Year Guidance Shakes Confidence

Perhaps most damaging to investor sentiment was management's decision to trim full-year 2026 revenue growth guidance. Sportradar now expects constant-currency revenue growth of 19% to 21%, down from the prior outlook of 23% to 25%. On a reported basis, factoring in current exchange rates, revenue is projected at €1.518 billion to €1.533 billion. Adjusted EBITDA growth guidance was also tempered, now seen at 24% to 27% on a constant-currency basis.

The guidance cut signals that foreign exchange pressures and a decelerating U.S. sports betting market are creating stronger headwinds than previously anticipated. For a company already under scrutiny following a disappointing first quarter — where EPS missed estimates by over 130% — the lowered bar leaves little room for execution missteps in the second half of the year.

Broader Headwinds: Lawsuits and Analyst Pressure

Beyond the earnings release, SRAD has been navigating additional headwinds that have weighed on the stock. A securities class-action lawsuit was filed earlier this year alleging that the company made misleading statements about its compliance standards while engaging with certain gaming operators. Although management has not commented extensively on the litigation, the overhang has contributed to a cautious posture among institutional investors.

Analyst sentiment, while still skewing moderately bullish overall, has deteriorated in recent months. Jefferies downgraded the stock to Hold from Buy in April, slashing its price target from $30 to $14. Zacks Research downgraded SRAD to Strong Sell. Even bullish-leaning firms like Guggenheim have trimmed targets, lowering theirs to $28 from $30. The stock entered the session with a consensus Moderate Buy rating but with downward estimate momentum that has clearly spooked the market.

Market Context and Trading Activity

Monday's plunge in SRAD stands in stark contrast to the broader market, which was trading firmly in positive territory — the S&P 500, Dow Jones Industrial Average, and Nasdaq Composite all advanced during the session. This divergence confirms that the move was driven exclusively by company-specific catalysts rather than macroeconomic forces. Trading volume surged well above the daily average of approximately 2 million shares, reflecting intense selling pressure as investors digested the earnings report.

On the technical front, the stock sliced through its 50-day moving average of roughly $14.82 and its 200-day moving average near $16.08. The 52-week range, spanning from $11.66 to $32.22, now places SRAD perilously close to its annual low — a level that could serve as the next key support test if selling momentum persists.

What Comes Next for SRAD

The immediate focus for investors will be management's commentary during the earnings conference call, particularly any color on the trajectory of U.S. market growth, foreign exchange hedging strategies, and margin expectations for the second half. The company's recent strategic partnerships — including multi-year deals with prediction market platforms Kalshi and Polymarket, as well as the Wimbledon data rights extension — represent genuine growth opportunities, but the market is clearly demanding evidence that these can translate into accelerating revenue and sustainable profitability.

Upcoming quarterly reports will be scrutinized for signs of stabilization in U.S. betting-related revenue and traction with new product offerings like Playradar. Risks remain tilted to the downside if currency headwinds persist, if the class-action litigation escalates, or if execution on the IMG ARENA integration disappoints. Conversely, any upside surprise in the third quarter or a favorable resolution of legal overhangs could trigger a sharp relief rally, given the stock's deeply discounted valuation relative to its 52-week highs.

Trending AI Robots

In volatile markets, traders increasingly turn to technology-driven strategies to identify opportunities and manage risk. Tickeron's Trending AI Robots page curates a selection of the platform's strongest-performing AI trading bots, drawn from hundreds of available strategies covering thousands of tickers. Only bots that have demonstrated consistent strength under current market conditions make the cut — and they span a wide range of strategies, timeframes, and performance metrics. Exploring this curated list can help traders discover data-driven approaches suited to today's shifting market landscape.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: SRAD

Momentum Indicator for SRAD turns positive, indicating new upward trend

SRAD saw its Momentum Indicator move above the 0 level on July 31, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 88 similar instances where the indicator turned positive. In of the 88 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 54 cases where SRAD's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where SRAD advanced for three days, in of 284 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for SRAD turned negative on July 14, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at .

SRAD moved below its 50-day moving average on July 30, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for SRAD crossed bearishly below the 50-day moving average on July 28, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SRAD declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

SRAD broke above its upper Bollinger Band on July 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for SRAD entered a downward trend on July 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. SRAD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.156) is normal, around the industry mean (26.944). P/E Ratio (57.356) is within average values for comparable stocks, (78.990). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.637). Dividend Yield (0.000) settles around the average of (0.049) among similar stocks. P/S Ratio (3.025) is also within normal values, averaging (51.731).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SRAD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

Notable companies

The most notable companies in this group are Shopify Inc (NASDAQ:SHOP), Salesforce (NYSE:CRM), Uber Technologies (NYSE:UBER), ServiceNow Inc. (NYSE:NOW), Adobe (NASDAQ:ADBE), Datadog (NASDAQ:DDOG), Intuit (NASDAQ:INTU), Autodesk (NASDAQ:ADSK), Workday (NASDAQ:WDAY), Zoom Communications Inc (NASDAQ:ZM).

Industry description

Packaged software comprises multiple software programs bundled together and sold as a group. For example, Microsoft Office includes multiple applications such as Excel, Word, and PowerPoint. In some cases, buying a bundled product is cheaper than purchasing each item individually[s20] . Microsoft Corporation, Oracle Corp. and Adobe are some major American packaged software makers.

Market Cap

The average market capitalization across the Packaged Software Industry is 11.28B. The market cap for tickers in the group ranges from 291 to 400.93B. QH holds the highest valuation in this group at 400.93B. The lowest valued company is BLGI at 291.

High and low price notable news

The average weekly price growth across all stocks in the Packaged Software Industry was 3%. For the same Industry, the average monthly price growth was -4%, and the average quarterly price growth was -5%. BIYA experienced the highest price growth at 76%, while YAAS experienced the biggest fall at -87%.

Volume

The average weekly volume growth across all stocks in the Packaged Software Industry was 5%. For the same stocks of the Industry, the average monthly volume growth was -13% and the average quarterly volume growth was -41%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 52
P/E Growth Rating: 78
Price Growth Rating: 61
SMR Rating: 78
Profit Risk Rating: 94
Seasonality Score: -6 (-100 ... +100)
View a ticker or compare two or three
SRAD
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

Industry PackagedSoftware

Profile
Details
Industry
N/A
Address
Feldlistrasse 2
Phone
+41 715177200
Employees
4882
Web
https://www.sportradar.com
Interact to see
Advertisement
Chevron’s upcoming Q4 report highlights its first full quarters integrating Hess, following record Q3 production of 4.1 million barrels of oil equivalent per day (MMboe/d). Comparing CVX with ExxonMobil and Shell provides insight into how each supermajor is navigating a volatile oil market with prices hovering below $60 per barrel.
SoFi Technologies is set to report Q4 and full-year 2025 earnings on January 30, 2026, closing out a pivotal year for the digital finance platform. With its fiscal year ending December 31, the report follows a strong Q3 that featured record net revenue of $962 million and member growth to 12.6 million, a 35% year-over-year increase.
ASML reported Q4 2025 net sales of $9.7 billion, gross margin of 52.2%, net income of $2.8 billion, and record net bookings of $13.2 billion, including $7.4 billion in EUV orders.
IDEXX Laboratories (IDXX) reports Q4 2025 earnings on February 2, 2026, with analysts expecting continued strength in recurring revenue from companion animal diagnostics. Danaher (DHR) reports on January 28, while Thermo Fisher Scientific (TMO) follows in early February, with both facing low-single-digit core growth expectations across life sciences and diagnostics.
NIO Inc. (NIO) produced its one-millionth vehicle this week at its Hefei facility, closing out a record 2025 delivery total of 326,028 units, up 46.9% year over year. The milestone, announced January 6, reflects accelerating demand for core models such as the ES8 SUV and newer brands ONVO and Firefly.
Faraday Future Intelligent Electric Inc. (FFAI) shares traded near $1.02 this week following announcements of a non-binding $10 million stock purchase term sheet with AIxCrypto (AIxC) and preparations for a Stockholders’ Day on January 7, 2026. Trading volume spiked amid broader EV volatility, highlighting investor attention on FFAI’s pivot toward AI-enhanced mobility and robotics.
BTQ Technologies Corp. (BTQ), formerly BTQQF, launched the Bitcoin Quantum testnet this week—the first quantum-safe Bitcoin fork, 17 years after Bitcoin’s genesis block. The move coincided with inclusion in the $524.5 million VanEck Quantum Computing UCITS ETF, boosting European investor visibility.
VEU targets large- and mid-cap ex-U.S. stocks with ~3,800 holdings. VXUS offers broad all-cap exposure, including ~8,600 stocks across small-, mid-, and large-cap companies.
Apple (AAPL) reports Q1 FY2026 earnings on January 29, with consensus revenue at $138.5B and EPS at $2.67, supported by strong demand for iPhone 17 models, higher average selling prices, and continued Services growth. Microsoft (MSFT) reports Q2 FY2026 on January 28, expecting $80.3B revenue and $3.91 EPS, driven by Azure AI adoption and enterprise cloud expansion, though elevated capex spending (~$35B/quarter) remains under scrutiny.
Visa Inc. (V), the global payments network leader, reports Q1 FY2026 earnings on January 29, 2026, for the period ending December 31, 2025. This marks the start of FY2026 following a strong FY2025, where net revenue reached $40 billion (+11%) and EPS climbed to $11.47 (+14%). Investors are watching closely for insights into consumer spending, cross-border travel recovery, and digital payment adoption.
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.